Stifel's Paul Matteis covers earnings season and recent clinical data in biotech on Analyst Thursdays

blonca9
Feb 22, 2024
1 min read

Paul Matteis gives his take on biotech's start to the year and comments on Alnylam, Biogen, Vertex, KalVista, Denali, Acadia, Alector, Neurocrine, and more.

Recent Posts

See All

As federal funding for cancer research has been jeopardized at NIH and academia, Parker Institute for Cancer Immunotherapy is one private institution ready to step up and broaden its impact

Mount Sinai has embraced AI as a drug discovery tool by launching this month its new AI Small Molecule Drug Discovery Center - Professor Avner Schlessinger tells us why

Jones Healthcare & Technology Innovation Conference: Jones Research analysts Soumit Roy and Justin Walsh share their take on biotech and comment on companies they cover

Stifel's Paul Matteis covers earnings season and recent clinical data in biotech on Analyst Thursdays

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight